Endothelin-1, big endothelin-1, and nitric oxide in patients with chronic renal disease and hypertension

Journal of Clinical Laboratory Analysis

Volumn 23, Issue 6, 2009, Pages 347-356

  Mikulić, Ivanka ^a   Petrik, József ^b   Galešić, Krešimir ^c   Romić, Željko ^c   Čepelak, Ivana ^b   Zeljko Tomić, Monika ^a  

^a UNIVERSITY OF MOSTAR   (Bosnia and Herzegovina)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c University of Zagreb   (Croatia)

Author keywords

Big endothelin 1; Chronic renal disease; Endothelin 1; Hypertension; Nitric oxide

Indexed keywords

ENDOTHELIN 1; NITRIC OXIDE;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; URINALYSIS;

ADULT; ENDOTHELIN-1; FEMALE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NITRATES; NITRIC OXIDE; NITRITES; REGRESSION ANALYSIS; ROC CURVE; YOUNG ADULT;

EID: 73249129263     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20324     Document Type: Article

References (75)

1. Potter GS, Johnson RJ, Fink GD. Role of endothelin in hypertension of experimental chronic renal failure. Hypertension 1997;6:1578-1584.
2. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med 2003;139:761-776.
3. Jaber BL, Madias NE. Progression of chronic kidney disease: Can it be prevented or arrested? Am J Med 2005;118:1323-1330.
4. Parmar MS. Chronic renal disease. BMJ 2002;325:85-90.
5. Rabelink TJ, Kaasiager KAH, Stroes ESG, Koomans HA. Endothelin in renal pathophysiology: From experimental to therapeutic application. Kidney Int 1996;50:1827-1833.
6. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidone-sensitive metalloproteinase with acidic pH optimum. J Biol Chem 1995;270:15262-15268.
7. B receptors. Hypertension 2000;35:732-739.
8. Rabelink TJ, Stroes ESG, Bouter KP, Morrison P. Endothelin blockers and renal protection: A new strategy to prevent end-organ damage in cardiovascular disease? Cardiovasc Res 1998;39:543-549.
9. Sharma R, Coats AJS, Anker SD. The role of inflammatory mediators in chronic heart failure: Cytokines, nitric oxide, and endothelin-1. Int J Cardiol 2000;72:175-186.
10. Sofia M, Maniscalco M, Celentano L, et al. Abnormalities of renal endothelin during acute exacerbation in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2001;14:321-327.
11. Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 2004;53:2060-2066.
12. Pollock DM. Renal endothelin in hypertension. Curr Opin Nephrol Hypertens 2000;9:157-164.
13. Hand MF, Haynes WG, Webb DJ. Reduced endogenous endothelin-1-mediated vascular tone in chronic renal failure. Kidney Int 1999;55:613-620.
14. Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure. Circulation 2004;109:1186-1193.
15. Merta M, Reiterova J, Ryšava R, et al. Role of endothelin and nitric oxide in the pathogenesis of arterial hypertension in autosomal dominant polycystic kidney disease. Physiol Res 2003;52:433-437.
16. Benigni A, Remuzzi G. How renal cytokines and growth factors contribute to renal disease progression. Am J Kidney Dis 2001;37:21-24.
17. Zoja C, Benigni A, Camozzi D, et al. Combining lisinopril and L-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis. Kidney Int 2003;64:857-863.
18. Ignarro IJ, Cirino G, Casini A, et al. Nitric oxide as a signaling molecule in the vascular system. J Cardiovasc Pharmacol 1999;34:879-876.
19. Sharma SP. Nitric oxide and the kidney. Indian J Nephrol 2004;14:77-84.
20. Klahr S. The role of nitric oxide in hypertension and renal disease progression. Nephrol Dial Transplant 2001;16:60-62.
21. MacAllister R, Vallance P. Nitric oxide in essential and renal hypertension. J Am Soc Nephrol 1994;5:1057-1065.
22. Seccia TM, Maiolino G, Pessina AC, Rossi GP. The molecular basis of the interplay between endothelin-1 and nitric oxide and its relevance for atherosclerosis and arterial and pulmonary hypertesion. Vasc Dis Prevention 2005;2:53-66.
23. Cardillo C, Kilcoyne CM, Cannon III RO, Panza JA. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 2000;35:1237-1241.
24. Liu Z, Wildhirt SM, Weismuller S, et al. Nitric oxide and endothelin in the development of cardiac allograft vasculopathy. Atherosclerosis 1998;140:1-14.
25. Goligorsky MS, Budzikowski AS, Tsukahara H, Noiri E. Cooperation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. Clin Exp Pharmacol Physiol 1999;26:269-271.
26. Aiello S, Remuzzi G, Noris M. Nitric oxide/endothelin balance after nephron reduction. Kidney Int 1998;53:63-67.
27. Rossi GP, Seccia TM, Albertin G, Pessina AC. Measurement of endothelin: Clinical and research use. Ann Clin Biochem 2000;37:608-626.
28. Editorial. Nitric oxide determinations: Much ado about NO-thing? Clin Chem 1997;43:553-556.
29. Goligorsky MS, Tsukahara H, Magazine H, Andersen TT, Malik AB, Bahou WF. Termination of endothelin signaling: Role of nitric oxide. J Cell Physiol 1994;158:485-494.
30. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin A-receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998;97:752-756.
31. Ahlborg G, Lundberg JM. Nitric oxide-endothelin-1 interactions in humans. J Appl Physiol 1997;82:1593-1600.
32. Abassi ZA, Klein H, Golomb E, et al. Urinary endothelin: A possible biological marker of renal damage. Am J Hypertens 1993;6:1046-1054.
33. Brown M, Chou SJ, Porush JG. Endothelins and kidney disease. Nephron 1996;73:375-382.
34. Abassi ZA, Tate JE, Golomb E, et al. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension 1992;20:89-95.
35. King AJ, Brenner BM, Anderson S. Endothelin: A potent renal and systemic vasoconstrictor peptide. Am J Physiol 1989;256:1051-1058.
36. + exchange, c-fos expression, and mitogenesis in rat mesangial cells. J Clin Invest 1989;83:708-712.
37. Benigni A, Zoja C, Corna D, et al. Specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993;44:440-444.
38. De Mattia G, Cassone-Faldetta M, Bellini C, et al. Role of plasma and urinary endothelim-1 in early diabetic and hypertensive nephropathy. Am J Hypertens 1998;11:983-988.
39. Schnackenberg C, Patel AR, Kirchner KA, Granger JP. Nitric oxide, the kidney and hypertension. Clin Exp Pharmacol Physiol 1997;24:600-606.
40. Rabelink TJ, Bakris GL. The renin-angiotensin system in diabetic nephropathy: The enothelial connection. Miner Electrolyte Metab 1998;24:381-388.
41. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990;33:306-310.
42. Tarquini B, Perfetto F, Tarquini R, Cornelissen G, Halberg F. Endothelin-1 chronome indicates diabetic and vascular disease chronorisk. Peptides 1997;18:119-132.
43. Lee YL, Shin SJ, Tsai JH. Increased urinary endothelin-1-like immunoreactivity in NIDDM patients with albuminuria. Diabetes Care 1994;17:263-266.
44. Sharma K, Ziyadeh FN, Alzahabi B, et al. Increased renal production of transforming growth factor-β in patients with type II diabetes. Diabetes 1997;46:854-859.
45. Zoja C, Morigi M, Figliuzzi M, et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 1995;26:934-941.
46. Komers R, Anderson S. Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol 2003;284:1121-1137.
47. Kone BC. Localization and regulation of nitric oxide synthase isoforms in the kidney. Semin Nephrol 1999;19:230-241.
48. Sugimoto H, Shikata K, Matsuda M, et al. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 1998;41:1426-1434.
49. Craven PA, DeRubertis FR, Melhem M. Nitric oxide in diabetic nephropathy. Kidney Int 1997;60:46-53.
50. Tolins JP, Shultz PJ, Raij L, Brown DM, Mauer SM. Abnormal renal hemodynamic response to reduced renal perfusion pressure in diabetic rats: Role of NO. Am J Physiol 1993;265:886-895.
51. Bank N, Aynedjian HS. Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int 1993;43:1306-1312.
52. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: The role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004;25:971-1010.
53. Webb ML, Meek TD. Inhibitors of endothelin. Med Res Rev 1997;17:17-67.
54. Schiffrin EL. Vascular endothelin in hypertension. Vasc Pharmacol 2005;43:19-29.
55. Hirai Y, Adachi H, Fujiura Y, Hiratsuka A, Enomoto M, Imaziumi T. Plasma endothelin-1 level is related to renal function and smoking status but not to blood pressure: An epidemiological study. J Hypertens 2004;22:713-718.
56. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092-3095.
57. Bataineh A, Raij L. Angiotensin II, nitric oxide, and end-organ damage in hypertension. Kidney Int 1998;54:14-19.
58. Koyama H, Tabata T, Nishzawa Y, et al. Plasma endothelin levels in patients with uraemia. Lancet 1989;1:991-992.
59. Warrens AN, Cassidy MJD, Takahashi K, Ghatei MA, Bloom SR. Endothelin in renal failure. Nephrol Dial Transplant 1990;5:418-422.
60. Miyauchi T, Sugishita Y, Yamaguchi I, et al. Plasma concentrations of endothelin-1 and endothelin-3 are altered differently in various pathophysiological conditions in humans. J Cardiovasc Pharmacol 1991;17:394-397.
61. Web DJ, Cockcroft JR. Plasma immunoreactive endothelin in uraemia. Lancet 1989;1:1211.
62. Benigni A, Perico N, Gaspari F, et al. Increased renal endothelin production in rats with reduced renal mass. Am J Physiol 1991;260:331-339.
63. Brooks DP, Contino LC, Storer B, Ohlstein E. Increased endothelin excretion in rats with renal failure induced by partial nephrectomy. Br J Pharmacol 1991;104:987-989.
64. Orisio S, Benigni A, Bruzzi I, et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993;43:354-358.
65. Ohta K, Hirata Y, Shichiri M, et al. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 1991;39:307-311.
66. Dumont Y, D'Amours M, Lebel M, Larivière R. Supplementation with a low dose of L-arginine reduces blood pressure and endothelin-1 production in hypertensive uraemic rats. Nephrol Dial Transplant 2001;16:746-754.
67. Moeslinger T, Spickermann PG. Urea-induced inducible nitric oxide synthase inhibition and macrophage proliferation. Kidney Int 2001;78:2-8.
68. Aiello S, Noris M, Remuzzi G. Nitric oxide/L-arginine in uremia. Miner Electrolyte Metab 1999;25:384-390.
69. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 2000;58:1261-1266.
70. Li H, Wallerath T, Münzel T, Förstermann U. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide 2002;7:149-164.
71. Chalupsky K, Hua C. Endothelial dihydrofolate reductase: Critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. PNAS 2005;25:9056-9061.
72. Passauer J, Bussemaker E, Range U, Plug M, Gross P. Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium-dependent vasodilatation in normotensive patients on chronic hemodialysis. J Am Soc Nephrol 2000;11:1726-1734.
73. Hazen SL, Hazen SL, Zhang R, Shen Z. Formation of nitric oxide derived oxidants by myeloperoxidase in monocytes: Pathways for monocyte mediated protein nitration and lipid peroxidation in vivo. Circ Res 1999;85:950-958.
74. B in human kidney. Kidney Int 1993;44:36-42.
75. Nambi P, Pullen M, Wu HL, Aiyar N, Ohlstein EH, Edwards RM. Identification of endothelin receptor subtypes in human renal cortex and medulla using subtype-selective ligands. Endocrinology 1992;131:1081-1086.